SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Global Cancer Generics (Oral & Injectables) Market Outlook to 2018

[August 19, 2014]

Research and Markets: Global Cancer Generics (Oral & Injectables) Market Outlook to 2018

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/9gzt3d/global_cancer) has announced the addition of the "Global Cancer Generics Market Outlook 2018" report to their offering.

With the advent of novel and innovative technologies, industries like healthcare and pharmaceutical are scaling newer heights. One such market is the oncology market. With global cancer incidences rising to almost 14.1 Million in 2012 and several blockbuster cancer drugs losing their patent protection, the market for cancer generics is bound to experience skyrocketing growth.

According to this latest research report Global Cancer Generics Market Outlook 2018, the global oncology market touched a mark of US$ 91 Billion in 2013 and is poised to grow at a CAGR of approximately 6% over the next 5 year period. On the other hand, the market for cancer generics is expected to grow at 12%, reaching US$ 21 Billion by 2018. Patent expiry, low cost, and better life expectancy would be the major boosting factors for the cancer generics industry.

The report essentially elicits the cancer industry under 2 heads viz. global oncology market and global caner generics market. Hereunder, cancer incidences are discussed providin an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to major indications is also discussed in depth, with emphasis on current and future incidences, regional analysis and patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the market is also added.


Apart from the above mentioned study parameters the dossier also contains an analysis of the top notch global cancer generics manufacturers. On a holistic basis, the report is primarily inclined towards an in-depth study of the global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labelling Cancer Generics as a field with substantial growth potential over the next few years.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Global Cancer Drugs Market Outlook 2018

4. Global Cancer Generics Market Analysis 2018

5. Cancer Generic Drugs Industry

Oral Generic Drugs

  • Arimidex (Anastrozole)
  • Femara (Letrozole)
  • Hycamtin (Topotecan)
  • Stivarga (Regorafenib)
  • Tarceva (Erlotinib)
  • Xalkori (Crizotinib)
  • Xeloda (Capecitabine)

Generic Injectables

  • Camptosar (Irinotecan Hydrochloride)
  • Eloxatin (Oxaliplatin)
  • Gemzar (Gemcitabine Hydrochloride)
  • Navelbine (Vinorelbine Tartrate)
  • Platinol (Cisplatin)
  • Taxol (Paclitaxel)
  • Taxotere (Docetaxel)

6. Cancer Generics Market: Major Indications

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Stomach Cancer
  • Prostate Cancer

7. Market Dynamics

  • Indian Generic Cancer Drug Introduced in the US Market
  • Launch of Generic Drugs for Oncology
  • Increasing Cancer Burden Paving Way for Generics
  • Patent Expiry of Blockbuster Oncology Drugs
  • Strategic Collaborations

8. Key Players

  • Actavis Plc
  • Fresenius Kabi AG
  • Hospira
  • Mylan
  • Sun Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.

For more information visit http://www.researchandmarkets.com/research/9gzt3d/global_cancer


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.